On Demand Therapeutics Announces Novel Drug Delivery System for AMD
May 12, 2010
Submit Comments
A new company, a spin-off from another of Dr. Robert Langer’s MIT companies, has just come out of stealth mode and released details of its potentially breakthrough approach to delivering drugs on demand to the back of the eye. The new company, On Demand Therapeutics, has disclosed a laser activatable drug reservoir that can deliver a drug such as Avastin, for treating neovascular AMD, as needed to treat that disease. At least, that is the concept.
To read more about this potential breakthrough in on-demand drug delivery, please see my writeup on the company, including illustrations of the concept, along with several questions I have.
Comments (0)
Trackbacks
Print this post
Filed in Industry News, Macular Degeneration, New Technologies, Products, Research, Retina
You might also enjoy...
- New Drug Delivery Device May Treat Retinal Damage Caused by Diabetes
- Is Iluvien From Alimera Sciences the Future of Ophthalmic Drug Delivery?
- Contaminated Repackaged Avastin Causes Severe Eye Infections and Blindness
- Can External Drug Delivery System Improve Treatment of Retinal Disease?
- Will 2012 be the Year for Gene Therapy in Ophthalmology?
Comments
Jump down to form below to submit your own comments
